Type I interferon, anti-interferon antibodies, and COVID-19
Authors:
- 1 April 2021
- journal article
- editorial
- Published by Elsevier in The Lancet Rheumatology
- Vol. 3 (4) , e246-e247
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Autoantibodies against type I IFNs in patients with life-threatening COVID-19Science, 2020
- Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseasesCurrent Opinion in Rheumatology, 2020
- Anifrolumab in Systemic Lupus Erythematosus: Current Knowledge and Future ConsiderationsImmunotherapy, 2020
- Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical ClassificationJournal of Clinical Immunology, 2020
- Anti-Cytokine Autoantibodies in Systemic Lupus ErythematosusCells, 2019
- Functional Analysis of Anti-cytokine Autoantibodies Using Flow CytometryFrontiers in Immunology, 2019
- Prevalence and correlation of cytokine-specific autoantibodies with epidemiological factors and C-reactive protein in 8,972 healthy individuals: Results from the Danish Blood Donor StudyPLOS ONE, 2017
- Anticytokine Autoantibodies: Association with Infection and Immune DysregulationAntibodies, 2016
- Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiencyJournal of Clinical Investigation, 2015
- Association of endogenous anti–interferon‐α autoantibodies with decreased interferon‐pathway and disease activity in patients with systemic lupus erythematosusArthritis & Rheumatism, 2011